IXICO PLC (AIM:IXI, OTC:PHYOF) said it was selected by a leading European biopharmaceutical company to provide MRI and DAT-SPECT imaging services for a phase 2 clinical trial in Parkinson's disease (PD).
Under the contract, the neuro-imaging specialist will provide radiology and quantitative analysis services to support patient selection, safety, and efficacy analysis. The trial is expected to be delivered over a period of four and a half years, it said in a statement.
Condor Gold PLC (AIM:CNR, TSX:COG, OTC:CNDGF) said a metallurgical recovery of 91% will be used in the forthcoming feasibility study for the La India open pit in Nicaragua after final metallurgical tests demonstrated that gold recovery is independent of grade.
“91% metallurgical recovery over the life of mine is a terrific result and represents a significant de-risking of one of the most important variables in the development of a new mine at La India project and provides significant comfort to investors,” said chairman and chief executive Mark Child.
Open Orphan PLC (AIM:ORPH, OTC:OPORF) said its hVIVO arm has won a £6.2mln contract with a US biotechnology company to test its antiviral candidate, the third influenza human challenge study contract signed this year.
The hVIVO Influenza A model will be used in the clinical trials, which are expected to start before the end of the year and will be conducted at hVIVO's state-of-the-art facilities in London.